Merial launches arthritis trial
Duluth, Ga. - Merial launched a Previcox experience trial to collect post-approval data in a broader population of dogs and provide greater clinical experience data for veterinarians.
DULUTH, GA. — Merial launched a Previcox™ experience trial to collect post-approval data in a broader population of dogs and provide greater clinical experience data for veterinarians. The trial enrolled 1,000 dogs presenting with osteoarthritis to clinics throughout the United States, the company reports. The protocol was prepared in consultation with an independent advisory group of boarded surgeons. The hip was the most commonly diagnosed joint with osteoarthritis, the company reports, and although older and heavier dogs were most commonly represented in the osteoarthritis population, many younger dogs and dogs of lighter breeds also were affected. Most dogs improved within 10 days of initiation of firocoxib treatment with the observed benefits being greater at the end of the trial (day 40) than at one week after treatment began. There were no breed, age, weight or sex differences detected in the post-treatment initiation response, which occurred independently of previous NSAID treatment, Merial reports. The results of blood tests and clinical presentation were consistent with pre-registration studies that established the safety profile of the drug, the company reports.
For fastest response, call
(888) MERIAL-1
